U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

Originator

Approval Year

1921
1413
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
996
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8043
BACITRACIN

Approved Use

Uses first aid to help prevent infection in: •minor cuts •scrapes •burns

Launch Date

-6.7616637E11
Curative
Approved
8043
CORTISPORIN

Approved Use

For the treatment of corticosteroid-responsice dermatoses with secondary infection.

Launch Date

-4.0417919E11
Curative
Approved
8043
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

Launch Date

-4.7260799E10
PubMed

PubMed

TitleDatePubMed
Bacitracin: Methods of Production, Concentration, and Partial Purification, with a Summary of the Chemical Properties of Crude Bacitracin.
1948 Feb
IN VITRO STUDIES ON POSSIBLE SYNERGISTIC ACTION BETWEEN PENICILLIN AND BACITRACIN.
1949 Sep
In vitro sensitivity of Bacillus proteus and Pseudomonas aeruginosa to seven antibiotics; penicillin, streptomycin, bacitracin, polymyxin, aerosporin, aureomycin, and chloromycetin.
1950 Feb
Cholesterol 7alpha-hydroxylase. 2. Biochemical properties and participation of endogenous cholesterol in the assay in vitro.
1975 Jun 16
Detection by HPLC-ICP of metallothionein in serum of an epileptic child with valproate-associated hepatotoxicity.
1992 Dec
Differential dephosphorylation of the insulin receptor and its 160-kDa substrate (pp160) in rat adipocytes.
1992 Jul 15
Continuous administration of growth hormone does not prevent the decrease of IGF-I gene expression in zinc-deprived rats despite normalization of liver GH binding.
1998 Dec
Plasma apolipoprotein B-48, hepatic apolipoprotein B mRNA editing and apolipoprotein B mRNA editing catalytic subunit-1 mRNA levels are altered in zinc-deficient rats.
1999 Oct
Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene.
1999 Sep 10
The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.
2000 Feb 15
Cadmium mutagenicity and human nucleotide excision repair protein XPA: CD, EXAFS and (1)H/(15)N-NMR spectroscopic studies on the zinc(II)- and cadmium(II)-associated minimal DNA-binding domain (M98-F219).
2000 May
Heterogeneity of GABA(A) receptor-mediated responses in the human IMR-32 neuroblastoma cell line.
2000 May 15
Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein.
2000 Nov 28
Increased protein intake during recovery from zinc deficiency is accompanied by alterations in hypothalamic growth hormone releasing factor and somatostatin.
2001
Dietary zinc deficiency increases uroguanylin accumulation in rat kidney.
2001 Apr
cDNA array analysis identifies thymic LCK as upregulated in moderate murine zinc deficiency before T-lymphocyte population changes.
2001 Dec
Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT.
2001 Feb 28
Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc.
2001 Mar
p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis.
2001 May 15
[Effect of zinc deficiency and zinc replenishment on HOX3.5 gene expression in mouse embryos].
2001 Nov
Influence of dietary zinc deficiency during development on hepatic CYP2C11, CYP2C12, CYP3A2, CYP3A9, and CYP3A18 expression in postpubertal male rats.
2001 Nov 1
Isolation of GIF from porcine brain and studies of its zinc transfer kinetics with apo-carbonic anhydrase.
2002 Dec
Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle.
2002 Dec 13
Purification and characterization of cytosolic glycerol-3-phosphate dehydrogenase from skeletal muscle of jerboa (Jaculus orientalis).
2002 Feb
Attenuation of both apoptotic and necrotic actions of cadmium by Bcl-2.
2002 Jan
Allosteric modulation of beta2-adrenergic receptor by Zn(2+).
2002 Jan
Role of a copper-specific metallothionein of the blue crab, Callinectes sapidus, in copper metabolism associated with degradation and synthesis of hemocyanin.
2002 Jan 15
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.
2002 Jan 15
S-nitrosothiols react preferentially with zinc thiolate clusters of metallothionein III through transnitrosation.
2002 Jul 2
Partitioning of accumulated trace metals in the talitrid amphipod crustacean Orchestia gammarellus: a cautionary tale on the use of metallothionein-like proteins as biomarkers.
2002 Jun
White-sided dolphin metallothioneins: purification, characterisation and potential role.
2002 Mar
Reactive oxygen species modulate Zn(2+)-induced apoptosis in cancer cells.
2002 Mar 1
Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor.
2002 May 10
Cloning and characterization of a novel mammalian zinc transporter, zinc transporter 5, abundantly expressed in pancreatic beta cells.
2002 May 24
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents.
2002 Nov
Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation.
2002 Nov
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation.
2002 Oct
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).
2002 Oct 25
Evidence for non-isostructural replacement of Zn(2+) with Cd(2+) in the beta-domain of brain-specific metallothionein-3.
2002 Sep 11
Induction of metallothionein by zinc protects from daunorubicin toxicity in rats.
2002 Sep 30
Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts.
2003 Aug
Mechanisms of Zn(2+)-induced signal initiation through the epidermal growth factor receptor.
2003 Aug 15
Redox labile site in a Zn4 cluster of Cu4,Zn4-metallothionein-3.
2003 Aug 19
Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice.
2003 Jan
A novel class of ligand-gated ion channel is activated by Zn2+.
2003 Jan 10
Differential effects of zinc on functionally distinct human growth hormone mutations.
2003 Jul
Copper reduction by copper binding proteins and its relation to neurodegenerative diseases.
2003 Mar
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase.
2003 May 2
O6-alkylguanine-DNA alkyltransferase: low pKa and high reactivity of cysteine 145.
2003 Sep 23
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants.
2004 Mar
Patents

Patents

03943143
6
03959300
5
03959322
51
03965108
5
03983245
10
03989685
8
03991123
6
04039353
5
04061771
10
04080330
6
04138410
10
04147693
6
04166131
12
04166816
10
04194049
5
04234517
7
04262000
6
04262013
6
04276363
5
04307243
5
04308208
7
04331676
17
04347246
6
04374139
5
04382949
5
04400492
8
04440685
11
04443365
8
04443631
5
04481142
5
04497738
7
04497817
6
04505911
5
04515948
7
04518603
5
04525361
15
04543430
5
04544458
5
04549192
5
04568782
5
04570171
6
04622403
5
04654363
6
US2498165
5
US2834711 A
5

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration: Topical
In Vitro Use Guide
The MIC value was 32 mg/L for Staphylococcus aureus wild type strain after 48h incubation at 37°C.
Name Type Language
BACITRACIN
EP   HSDB   INN   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
TOPITRACIN
Common Name English
NSC-755905
Code English
LANABIOTIC COMPONENT BACITRACIN
Common Name English
BACITRACIN [WHO-IP]
Common Name English
PENITRACIN
Common Name English
BACITRACIN [EP MONOGRAPH]
Common Name English
MYCITRACIN COMPONENT BACITRACIN
Common Name English
FORTRACIN
Common Name English
BACITRACIN [VANDF]
Common Name English
BACIIM
Brand Name English
BACITRACIN [USP]
Common Name English
PARENTRACIN
Common Name English
BACITRACIN [USP MONOGRAPH]
Common Name English
BACIGUENT
Brand Name English
BACI-RX
Brand Name English
BACITRACIN [ORANGE BOOK]
Common Name English
BACILLIQUIN
Common Name English
BACITRACIN [WHO-DD]
Common Name English
BACITRACIN [HSDB]
Common Name English
BACITRACINUM [WHO-IP LATIN]
Common Name English
BACITRACIN COMPONENT OF MYCITRACIN
Common Name English
ZUTRACIN
Common Name English
BACITRACIN COMPONENT OF LANABIOTIC
Common Name English
TROPITRACIN
Common Name English
BACITRACIN [INN]
Common Name English
BACITRACIN(NON-INJECTABLE) [WHO-IP]
Common Name English
BACITRACIN [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 1284
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
WHO-VATC QR02AB04
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
WHO-ATC J01XX10
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
CFR 21 CFR 333.120
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
CFR 21 CFR 524.155
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
WHO-ATC R02AB04
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
CFR 21 CFR 556.70
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
EPA PESTICIDE CODE 6302
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
CFR 21 CFR 333.110
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
CFR 21 CFR 524.154
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
CFR 21 CFR 520.154
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
WHO-ATC D06AX05
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
WHO-VATC QJ01XX10
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
WHO-VATC QD06AX05
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
WHO-VATC QA07AA93
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
Code System Code Type Description
WIKIPEDIA
BACITRACIN
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
ECHA (EC/EINECS)
215-786-2
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
EVMPD
SUB00652MIG
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
RXCUI
1291
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
BACITRACIN
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures.
DRUG BANK
DB00626
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
FDA UNII
58H6RWO52I
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
NCI_THESAURUS
C295
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
INN
1167
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
MERCK INDEX
M2197
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY Merck Index
NDF-RT
N0000008479
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY Decreased Cell Wall Synthesis & Repair [PE]
LACTMED
Bacitracin
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
MESH
D001414
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
CAS
1405-87-4
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200558
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
DRUG CENTRAL
281
Created by admin on Fri Jun 25 21:02:55 UTC 2021 , Edited by admin on Fri Jun 25 21:02:55 UTC 2021
PRIMARY
All of the following components must be present:
Structure of BACITRACIN B2
Structure of BACITRACIN B3
Structure of BACITRACIN B1
Structure of BACITRACIN A
ACTIVE MOIETY
BACITRACIN
Definition References
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966